Development of Molecules Antagonizing Heparan Sulfate Proteoglycans.
Journal
Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
Heparan sulfate proteoglycans (HSPGs) occur in almost every tissue of the human body and consist of a protein core, with covalently attached glycosaminoglycan polysaccharide chains. These glycosaminoglycans are characterized by their polyanionic nature, due to sulfate and carboxyl groups, which are distributed along the chain. These chains can be modified by different enzymes at varying positions, which leads to huge diversity of possible structures with the complexity further increased by varying chain lengths. According to their location, HSPGs are divided into different families, the membrane bound, the secreted extracellular matrix, and the secretory vesicle family. As members of the extracellular matrix, they take part in cell-cell communication processes on many levels and with different degrees of involvement. Of particular therapeutic interest is their role in cancer and inflammation as well as in infectious diseases. In this review, we give an overview of the current status of medical approaches to antagonize HSPG function in pathology.
Identifiants
pubmed: 33794555
doi: 10.1055/s-0041-1725067
doi:
Substances chimiques
Heparan Sulfate Proteoglycans
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-332Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
None declared.